1,162 results on '"Pugh, Trevor J."'
Search Results
52. PRMT5 inhibition disrupts splicing and stemness in glioblastoma
53. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
54. Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas
55. Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: An evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders
56. Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition
57. Comprehensive molecular assessment of mismatch repair deficiency in Lynch associated ovarian cancers using next generation sequencing panel
58. Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA
59. Current and new frontiers in hereditary cancer surveillance: Opportunities for liquid biopsy
60. Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
61. Supplementary Figure S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
62. Data from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
63. Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal
64. Transplant Oncology in Primary and Metastatic Liver Tumor: Principles, Evidence and Opportunities
65. DNA hypermethylation within TERT promoter upregulates TERT expression in cancer
66. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
67. Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours
68. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations.
69. Characterizing Risk Factors for Hospitalization and Clinical Characteristics in a Cohort of COVID-19 Patients Enrolled in the GENCOV Study
70. Identification of intratumoral and peripheral T-cell receptor (TCR) repertoire features associated with acquired (Ar) and primary (Pr) resistance to immune checkpoint inhibitors (ICI).
71. MEDIPIPE: an automated and comprehensive pipeline for cfMeDIP-seq data quality control and analysis
72. Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
73. Wnt activation as a therapeutic strategy in medulloblastoma
74. Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor
75. Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer
76. Comprehensive molecular assessment of mismatch repair deficiency in Lynch associated ovarian cancers using next generation sequencing panel.
77. Sensitive tumour detection and classification using plasma cell-free DNA methylomes
78. Supplementary Data S3 from Multiple Germline Events Contribute to Cancer Development in Patients with Li-Fraumeni Syndrome
79. FIGURE 2 from Multiple Germline Events Contribute to Cancer Development in Patients with Li-Fraumeni Syndrome
80. FIGURE 3 from Multiple Germline Events Contribute to Cancer Development in Patients with Li-Fraumeni Syndrome
81. TABLE 1 from Multiple Germline Events Contribute to Cancer Development in Patients with Li-Fraumeni Syndrome
82. TABLE 2 from Multiple Germline Events Contribute to Cancer Development in Patients with Li-Fraumeni Syndrome
83. FIGURE 1 from Multiple Germline Events Contribute to Cancer Development in Patients with Li-Fraumeni Syndrome
84. FIGURE 5 from Multiple Germline Events Contribute to Cancer Development in Patients with Li-Fraumeni Syndrome
85. FIGURE 4 from Multiple Germline Events Contribute to Cancer Development in Patients with Li-Fraumeni Syndrome
86. Supplementary Figures S1-S12 from Multiple Germline Events Contribute to Cancer Development in Patients with Li-Fraumeni Syndrome
87. Data from Multiple Germline Events Contribute to Cancer Development in Patients with Li-Fraumeni Syndrome
88. Table TS6 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma
89. Data from AACR Project GENIE: 100,000 Cases and Beyond
90. Figure S1 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma
91. Supplementary Table from AACR Project GENIE: 100,000 Cases and Beyond
92. Supplementary Figure from AACR Project GENIE: 100,000 Cases and Beyond
93. Data from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma
94. Abstract 4256: cBioPortal for Cancer Genomics
95. Data from IL6 Induces an IL22+ CD8+ T-cell Subset with Potent Antitumor Function
96. Abstract 6667: Pan-cancer assessment of tumour and peripheral T-cell receptor repertoire dynamics in patients treated with immune checkpoint inhibitors
97. Supplementary Figures and Tables from IL6 Induces an IL22+ CD8+ T-cell Subset with Potent Antitumor Function
98. Supplementary Table from Mutations in Noncoding Cis-Regulatory Elements Reveal Cancer Driver Cistromes in Luminal Breast Cancer
99. Data from AACR Project GENIE: Powering Precision Medicine through an International Consortium
100. Data from Mutations in the RAS/MAPK Pathway Drive Replication Repair–Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.